Mayne Pharma
Manufacturing · Australia · 201-500 Employees
View Company Info for Free
Overview
Headquarters
1538 Main North Rd, Salisbury South, Sou...Phone Number
+61 882092666Website
www.maynepharma.comRevenue
$403.6 MillionStock Symbol
MYXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Mayne Pharma
Mayne Pharma Group Limited is an ASX-listed specialty pharmaceutical company headquartered in Salisbury South, South Australia, Australia, with U.S. operations based in Raleigh, North Carolina. The company focuses on the commercialization of branded and generic pharmaceuticals, with core therapeutic areas spanning women's health, dermatology, and infectious disease. Mayne Pharma operates through three business segments Women's Health, Dermatology, and International distributing products across Australia, New Zealand, the United States, Canada, Europe, and Asia. The company also offers full-service contract development and manufacturing (CDMO) capabilities, specializing in novel oral and topical dose forms, including pharmaceutical development, analytical testing, and commercial manufacturing for clients worldwide. With over 40 years of experience in developing oral drug delivery systems, Mayne Pharma markets a broad portfolio of branded and generic products under names such as NextstelRead more
Mayne Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mayne Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Mayne Pharma has new funding data
Congratulate Masked Content for being promoted to Masked Content at Mayne Pharma
Mayne Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Mayne Pharma is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Mayne Pharma launches new products
Earning: See what the market has to say on Mayne Pharma recently announced quarterly report
Check if Mayne Pharma has recently received funding, and reach out quickly before it becomes old news!
Click to see if Mayne Pharma had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Mayne Pharma
Compare insights from companies similar to Mayne Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Mayne Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Mayne Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Mayne Pharma.
Mayne Pharma financials insights
Gather financial insights about Mayne Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Debt
$125M
Mayne Pharma Tech Stack
A closer look at the technologies used by Mayne Pharma
See more technologies
Most Recent Scoops
Earnings
Mayne Pharma has reported that its underlying EBITDA for fiscal year 2026 was impacted by several factors, including unfavorable foreign exchange of approximately AUD 1.9 million, short-term incentives of approximately AUD 7.1 million recognized in fiscal year 2026 versus none in fiscal year 2025, and the absence of prior-period managed care true-up benefits of approximately USD 5.6 million recognized in fiscal year 2025.
Earnings, Accounting, Financial Reporting, Finance
Earnings
Mayne Pharma has reported a decrease in cash and marketable securities from AUD 100.4 million at June 30, 2025 to AUD 80 million at June 30, 2026, with the movement driven by Cosette litigation and transactional costs of AUD 12.6 million, royalty payments of approximately AUD 12.5 million, and an earn-out payment of AUD 10.3 million for the TWYNEO and EPSOLAY acquisitions, partially offset by underlying operating cash generation of approximately AUD 34.5 million.
Acquisitions, Finance, Financial Transactions
Earnings
Mayne Pharma has reported revenue of AUD 383.7 million for fiscal year 2026, down 6% from AUD 408.1 million in fiscal year 2025, with the decline driven by Australian dollar appreciation against the US dollar, a decline in dermatology revenue from the loss of certain insurance coverage and competitive erosion, and a decline in international revenue as the company transitioned its portfolio mix toward higher-margin products and exited certain lines.
Earnings, Finance
Person-Based
Pharmaceuticals
Person-Based
Medical Research, Pharmaceuticals
Mayne Pharma News & Media
Mayne Pharma Group Limited (MAYNF) Q4 2026 Earnings Call Transcript
Mayne Pharma Group Limited (MAYNF) Q4 2026 Earnings Call August 26, 2026 7:30 PM EDTCompany ParticipantsAaron Gray - Chief Executive OfficerGriffin Buchanan...Mayne Pharma growth strategy in Women’s health - ASX SMIDcaps Conference
Mayne Pharma Group Limited CEO Aaron Gray talked with Jonathan Jackson from Proactive at the Small and Mid-Cap Conference about the company’s strategy, product portfolio, and recent H1 results, highlighting its focus on women’s health and dermatology markets in the United States. Gray explained that Mayne Pharma operates across three business units, with two generating all revenue from the US, focused on women’s health and dermatology, while a third international unit covers Australia and otherMayne Pharma Group Ltd (MAYNF) (H1 2026) Earnings Call Highlights: Strategic Growth Amidst ...
Mayne Pharma Group Ltd (MAYNF) reports strong gross margin improvements and strategic advancements in Women's Health and Dermatology, despite facing competitive and legal challenges.Mayne Pharma CEO Shawn Patrick O'Brien replaced by CFO Aaron Gray - Capital Brief
Mayne Pharma CEO Shawn Patrick O’Brien stepped down on 20 February and has been replaced by CFO Aaron Gray in the wake of its collapsed $600 million deal to be acquired by Cosette Pharmaceuticals.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Mayne Pharma
Sign Up For FreeTo access detailed company insights
Mayne Pharma Group Limited is an ASX-listed specialty pharmaceutical company headquartered in Salisbury South, South Australia, Australia, with U.S. operations based in Raleigh, North Carolina. The company focuses on the commercialization of branded and generic pharmaceuticals, with core therapeutic areas spanning women's health, dermatology, and i... Read More
